Status of PCSK9 Monoclonal Antibodies in Australia

Daniel J. Scherer, Adam J. Nelson, Richard O'Brien, Karam M. Kostner, David L. Hare, David M. Colquhoun, Philip J. Barter, Phil Aylward, Stephen J. Nicholls, Gerald F. Watts

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb) have progressed from showing marked low density lipoprotein cholesterol lowering in early phase trials through to reducing cardiovascular events in large clinical outcome trials. Recently in Australia, the indication for evolocumab has been expanded to include both heterozygous and homozygous familial hypercholesterolaemia under the Pharmaceutical Benefits Scheme (PBS). With prices remaining high currently their use in non-familial hypercholesterolaemia in Australia remains by private prescription only at this stage. This manuscript summarises the major outcomes trials of the PCSK9 mAbs and the secondary analyses that have assessed their benefits in high risk patient groups, and describes the consensus of authors on which patients would most likely benefit from PCSK9 mAb therapy.

LanguageEnglish
Pages1571-1579
Number of pages9
JournalHeart Lung and Circulation
Volume28
Issue number10
DOIs
Publication statusPublished - 1 Oct 2019

Keywords

  • Atherosclerosis
  • Cardiovascular risk
  • Lipids
  • PCSK9 inhibitors

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Scherer, D. J., Nelson, A. J., O'Brien, R., Kostner, K. M., Hare, D. L., Colquhoun, D. M., ... Watts, G. F. (2019). Status of PCSK9 Monoclonal Antibodies in Australia. Heart Lung and Circulation, 28(10), 1571-1579. https://doi.org/10.1016/j.hlc.2019.04.014
Scherer, Daniel J. ; Nelson, Adam J. ; O'Brien, Richard ; Kostner, Karam M. ; Hare, David L. ; Colquhoun, David M. ; Barter, Philip J. ; Aylward, Phil ; Nicholls, Stephen J. ; Watts, Gerald F. / Status of PCSK9 Monoclonal Antibodies in Australia. In: Heart Lung and Circulation. 2019 ; Vol. 28, No. 10. pp. 1571-1579.
@article{8473b2b2c7cb4f78b5b8595ee78fd4c3,
title = "Status of PCSK9 Monoclonal Antibodies in Australia",
abstract = "Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb) have progressed from showing marked low density lipoprotein cholesterol lowering in early phase trials through to reducing cardiovascular events in large clinical outcome trials. Recently in Australia, the indication for evolocumab has been expanded to include both heterozygous and homozygous familial hypercholesterolaemia under the Pharmaceutical Benefits Scheme (PBS). With prices remaining high currently their use in non-familial hypercholesterolaemia in Australia remains by private prescription only at this stage. This manuscript summarises the major outcomes trials of the PCSK9 mAbs and the secondary analyses that have assessed their benefits in high risk patient groups, and describes the consensus of authors on which patients would most likely benefit from PCSK9 mAb therapy.",
keywords = "Atherosclerosis, Cardiovascular risk, Lipids, PCSK9 inhibitors",
author = "Scherer, {Daniel J.} and Nelson, {Adam J.} and Richard O'Brien and Kostner, {Karam M.} and Hare, {David L.} and Colquhoun, {David M.} and Barter, {Philip J.} and Phil Aylward and Nicholls, {Stephen J.} and Watts, {Gerald F.}",
year = "2019",
month = "10",
day = "1",
doi = "10.1016/j.hlc.2019.04.014",
language = "English",
volume = "28",
pages = "1571--1579",
journal = "Heart, lung & circulation",
issn = "1443-9506",
publisher = "Wiley-Blackwell",
number = "10",

}

Scherer, DJ, Nelson, AJ, O'Brien, R, Kostner, KM, Hare, DL, Colquhoun, DM, Barter, PJ, Aylward, P, Nicholls, SJ & Watts, GF 2019, 'Status of PCSK9 Monoclonal Antibodies in Australia', Heart Lung and Circulation, vol. 28, no. 10, pp. 1571-1579. https://doi.org/10.1016/j.hlc.2019.04.014

Status of PCSK9 Monoclonal Antibodies in Australia. / Scherer, Daniel J.; Nelson, Adam J.; O'Brien, Richard; Kostner, Karam M.; Hare, David L.; Colquhoun, David M.; Barter, Philip J.; Aylward, Phil; Nicholls, Stephen J.; Watts, Gerald F.

In: Heart Lung and Circulation, Vol. 28, No. 10, 01.10.2019, p. 1571-1579.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Status of PCSK9 Monoclonal Antibodies in Australia

AU - Scherer, Daniel J.

AU - Nelson, Adam J.

AU - O'Brien, Richard

AU - Kostner, Karam M.

AU - Hare, David L.

AU - Colquhoun, David M.

AU - Barter, Philip J.

AU - Aylward, Phil

AU - Nicholls, Stephen J.

AU - Watts, Gerald F.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb) have progressed from showing marked low density lipoprotein cholesterol lowering in early phase trials through to reducing cardiovascular events in large clinical outcome trials. Recently in Australia, the indication for evolocumab has been expanded to include both heterozygous and homozygous familial hypercholesterolaemia under the Pharmaceutical Benefits Scheme (PBS). With prices remaining high currently their use in non-familial hypercholesterolaemia in Australia remains by private prescription only at this stage. This manuscript summarises the major outcomes trials of the PCSK9 mAbs and the secondary analyses that have assessed their benefits in high risk patient groups, and describes the consensus of authors on which patients would most likely benefit from PCSK9 mAb therapy.

AB - Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAb) have progressed from showing marked low density lipoprotein cholesterol lowering in early phase trials through to reducing cardiovascular events in large clinical outcome trials. Recently in Australia, the indication for evolocumab has been expanded to include both heterozygous and homozygous familial hypercholesterolaemia under the Pharmaceutical Benefits Scheme (PBS). With prices remaining high currently their use in non-familial hypercholesterolaemia in Australia remains by private prescription only at this stage. This manuscript summarises the major outcomes trials of the PCSK9 mAbs and the secondary analyses that have assessed their benefits in high risk patient groups, and describes the consensus of authors on which patients would most likely benefit from PCSK9 mAb therapy.

KW - Atherosclerosis

KW - Cardiovascular risk

KW - Lipids

KW - PCSK9 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85065569958&partnerID=8YFLogxK

U2 - 10.1016/j.hlc.2019.04.014

DO - 10.1016/j.hlc.2019.04.014

M3 - Review article

VL - 28

SP - 1571

EP - 1579

JO - Heart, lung & circulation

T2 - Heart, lung & circulation

JF - Heart, lung & circulation

SN - 1443-9506

IS - 10

ER -

Scherer DJ, Nelson AJ, O'Brien R, Kostner KM, Hare DL, Colquhoun DM et al. Status of PCSK9 Monoclonal Antibodies in Australia. Heart Lung and Circulation. 2019 Oct 1;28(10):1571-1579. https://doi.org/10.1016/j.hlc.2019.04.014